Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a specific type of kidney cancer called clear cell renal cell carcinoma (ccRCC) that has spread or cannot be surgically removed.
- People whose cancer has continued to grow after receiving standard treatments, or who have declined standard treatments.
- People who are in relatively good general health, able to carry out light activity and care for themselves (as measured by a standard health scoring system called ECOG PS, with a score of 0 or 1).
- People whose doctors estimate they have a life expectancy of at least 12 weeks.
- People who have a tumor tissue sample available — either a new sample or one stored from a previous biopsy — as this is required for enrollment.
- People whose cancer can be measured on scans using a standard method called RECIST v1.1.
- People with blood counts, liver function, and kidney function within acceptable ranges (specific lab value thresholds apply — confirm with trial site).
- People who are able to swallow tablets or capsules and do not have any condition that would stop the study medication from being properly absorbed by the body.
Who may not be able to join:
- People whose kidney cancer is predominantly a type other than clear cell (non-clear cell subtypes).
- People who have cancer that has spread to the lining around the brain or spinal cord, or who have active brain metastases causing symptoms (some exceptions may apply for previously treated, symptom-free brain metastases — confirm with trial site).
- People with a current or past history of another cancer (some exceptions may apply — confirm with trial site).
- People with a history of Hepatitis B, Hepatitis C, or HIV infection.
- Additional exclusion criteria exist under the full study protocol — confirm with trial site.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Klaus Wagner, MD, PhD, Neomorph, Inc
Phone: +1 858-428-9800
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency and severity of treatment emergent adverse events (TEAEs) of NEO-811 as a single agent.; Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of NEO-811 as a single agent.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.